Biologic drugs for stubborn folliculitis decalvans
Treatments studied
Part of Skin clinical trials.
This trial tests three different biologic medications (adalimumab, ustekinumab, and baricitinib) to see if they can help people with a hard-to-treat scalp condition called folliculitis decalvans that hasn't improved with antibiotics. The study lasts 6 months and aims to find a better treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with folliculitis decalvans (a type of scalp inflammation) confirmed by a skin biopsy.
- Your condition is moderate to severe (score of 3 or 4 on a scale), and you have tried at least two different antibiotic treatments in the last 2 years.
- You have a normal chest X-ray taken within the last 3 months.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you use effective birth control if needed.
- You do not have a history of heart attack, heart failure, cancer (except cured skin cancer), heavy smoking, or other serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining two drugs, dupilumab and tofacitinib, works better for moderate to severe eczema in adults than either alone. It may help people whose eczema is not well controlled with standard treatments.
This trial tests a cream called delgocitinib to see if it can reduce redness and scaling in people with frontal fibrosing alopecia, a type of hair loss. It may help improve your symptoms if other treatments haven't worked.
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
This study compares two medicines, ustekinumab and upadacitinib, to see which works better for people with Crohn's disease that hasn't improved with other treatments. Both are taken as injections or pills and aim to reduce inflammation and help you feel better.
This study tests if the medication upadacitinib can help people whose eyelid rash has not improved with prescription creams. It's for adults who have had eyelid dermatitis for at least two months and have tried at least one prescribed cream that didn't work.
This trial tests two medications, secukinumab and tofacitinib, to see which works better for moderate to severe hidradenitis suppurativa (a skin condition causing painful bumps) in Chinese patients. The goal is to find a more effective treatment option.
Hear when a new Folliculitis Decalvans (FD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.